GLYCOMACROPEPTIDE FORMULA WITH DOCOSAHEXAENOIC ACID AND LOW PHENYLALANINE
Information current as at: 1 June 2026
The pharmaceutical company has withdrawn their submission for this medicine prior to the medicine being considered at the PBAC meeting.
PBAC meeting date: March 2024
Submission Details
- Brand name:
-
- PKU GMPro® ULTRA LQ
- Form and strength:
- Please search for and view the medicine's Public Summary Document (PSD) for more information
- Submission sponsor:
- Nutricia Australia Pty Limited
- Condition/indication:
(therapeutic use) -
- Phenylketonuria
- Listing requested:
- Please see PSD for more information
- Funding program:
- Please see PSD for more information
- Request authority level:
- Please see PSD for more information
- PBAC Submission type:
- New listing (Category 3)
- Comment:
- Withdrawn
- Other PBAC consideration:
- --
Progress Details
-
Submission received for: - March 2024 PBAC meeting
-
Opportunity for consumer comment: - Open 22/11/2023 and close 31/01/2024 (see PBS Website)
-
PBAC meeting: - Held on 13/03/2024
-
PBAC outcome published: - Not Applicable (see PBAC Outcomes)
-
Lodgement of required documentation: - Not applicable
-
Agreement to listing arrangements: - Not applicable
-
Government processes: - Not applicable
-
Medicine listed on the PBS: - Not applicable
PBAC Outcome
Case ID
a829
Page last updated
31 March 2026
v.9.19
